|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hollingsworth JM, Miller DC, Daignault S
and Hollenbeck BK: Five-year survival after surgical treatment for
kidney cancer: A population-based competing risk analysis. Cancer.
109:1763–1768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McDermott DF, Regan MM, Clark JI, Flaherty
LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff
MS, et al: Randomized phase III trial of high-dose interleukin-2
versus subcutaneous interleukin-2 and interferon in patients with
metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005.
View Article : Google Scholar
|
|
4
|
Kroeger N, Choueiri TK, Lee JL, Bjarnason
GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha
SY, et al: Survival outcome and treatment response of patients with
late relapse from renal cell carcinoma in the era of targeted
therapy. Eur Urol. 65:1086–1092. 2014. View Article : Google Scholar
|
|
5
|
Koshkin VS and Rini BI: Emerging
therapeutics in refractory renal cell carcinoma. Expert Opin
Pharmacother. 17:1225–1232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mains PE, Kemphues KJ, Sprunger SA,
Sulston IA and Wood WB: Mutations affecting the meiotic and mitotic
divisions of the early Caenorhabditis elegans embryo. Genetics.
126:593–605. 1990.PubMed/NCBI
|
|
7
|
Kent D, Bush EW and Hooper JE: Roadkill
attenuates Hedgehog responses through degradation of Cubitus
interruptus. Development. 133:2001–2010. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Ghanim M, Xue L, Brown CD, Iossifov
I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, et al:
Analysis of Drosophila segmentation network identifies a JNK
pathway factor overexpressed in kidney cancer. Science.
323:1218–1222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Q, Zhang L, Wang B, Ou CY, Chien CT
and Jiang J: A hedgehog-induced BTB protein modulates hedgehog
signaling by degrading Ci/Gli transcription factor. Dev Cell.
10:719–729. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol
JH, Baek SH, Chiba T, Tanaka K, Bang OS, et al: BTB
domain-containing speckle-type POZ protein (SPOP) serves as an
adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase.
J Biol Chem. 281:12664–12672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hernández-Muñoz I, Lund AH, van der Stoop
P, Boutsma E, Muijrers I, Verhoeven E, Nusinow DA, Panning B,
Marahrens Y and van Lohuizen M: Stable X chromosome inactivation
involves the PRC1 Polycomb complex and requires histone MACROH2A1
and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA.
102:7635–7640. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gordan JD, Lal P, Dondeti VR, Letrero R,
Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK,
Keith B, et al: HIF-alpha effects on c-Myc distinguish two subtypes
of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell.
14:435–446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sato Y, Yoshizato T, Shiraishi Y, Maekawa
S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki
H, et al: Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su D, Stamatakis L, Singer EA and
Srinivasan R: Renal cell carcinoma: Molecular biology and targeted
therapy. Curr Opin Oncol. 26:321–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li G, Ci W, Karmakar S, Chen K, Dhar R,
Fan Z, Guo Z, Zhang J, Ke Y, Wang L, et al: SPOP promotes
tumorigenesis by acting as a key regulatory hub in kidney cancer.
Cancer Cell. 25:455–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong
RC, Du Y, Wang B, Authement C, Hernandez E, et al: Loss of DAB2IP
in RCC cells enhances their growth and resistance to mTOR-targeted
therapies. Oncogene. Feb 15–2016.(Epub ahead of print). View Article : Google Scholar
|
|
17
|
Zhou J, Zhu G, Huang J, Li L, Du Y, Gao Y,
Wu D, Wang X, Hsieh JT, He D, et al: Non-canonical GLI1/2
activation by PI3K/AKT signaling in renal cell carcinoma: A novel
potential therapeutic target. Cancer Lett. 370:313–323. 2016.
View Article : Google Scholar
|
|
18
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muglia VF and Prando A: Renal cell
carcinoma: Histological classification and correlation with imaging
findings. Radiol Bras. 48:166–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eggener S: TNM staging for renal cell
carcinoma: Time for a new method. Eur Urol. 58:517–519; discussion
519–521. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tania M, Khan MA and Fu J: Epithelial to
mesenchymal transition inducing transcription factors and
metastatic cancer. Tumour Biol. 35:7335–7342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sánchez-Tilló E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011. View Article : Google Scholar
|
|
25
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al-Ahmadie HA, Alden D, Qin LX, Olgac S,
Fine SW, Gopalan A, Russo P, Motzer RJ, Reuter VE and Tickoo SK:
Carbonic anhydrase IX expression in clear cell renal cell
carcinoma: An immunohistochemical study comparing 2 antibodies. Am
J Surg Pathol. 32:377–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hes O, Michal M, Kuroda N, Martignoni G,
Brunelli M, Lu Y, Adley BP, Alvarado-Cabrero I and Yang XJ:
Vimentin reactivity in renal oncocytoma: Immunohistochemical study
of 234 cases. Arch Pathol Lab Med. 131:1782–1788. 2007.PubMed/NCBI
|
|
28
|
Ozcan A, Zhai J, Hamilton C, Shen SS, Ro
JY, Krishnan B and Truong LD: PAX-2 in the diagnosis of primary
renal tumors: Immunohistochemical comparison with renal cell
carcinoma marker antigen and kidney-specific cadherin. Am J Clin
Pathol. 131:393–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peinado H, Quintanilla M and Cano A:
Transforming growth factor beta-1 induces snail transcription
factor in epithelial cell lines: Mechanisms for epithelial
mesenchymal transitions. J Biol Chem. 278:21113–21123. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kypta RM and Waxman J: Wnt/β-catenin
signalling in prostate cancer. Nat Rev Urol. 9:418–428. 2012.
View Article : Google Scholar : PubMed/NCBI
|
